代謝性アシドーシス(MA)治療薬の世界市場:インサイト・疫学・市場予測

◆英語タイトル:Metabolic Acidosis (MA)- Market Insight, Epidemiology and Market Forecast -2030
◆商品コード:DELV20JU076
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(76名様閲覧)USD6,950 ⇒換算¥729,750見積依頼/購入/質問フォーム
Three UserUSD10,425 ⇒換算¥1,094,625見積依頼/購入/質問フォーム
Site LicenseUSD13,900 ⇒換算¥1,459,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s “Metabolic Acidosis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Metabolic Acidosis, historical and forecasted epidemiology as well as the Metabolic Acidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Metabolic Acidosis market report provides current treatment practices, emerging drugs, Metabolic Acidosis market share of the individual therapies, current and forecasted Metabolic Acidosis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Metabolic Acidosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Brazil
China
Mexico

Study Period: 2017-2030

Metabolic Acidosis Disease Understanding and Treatment Algorithm
Metabolic acidosis is defined by an increase in the hydrogen-ion concentration in the systemic circulation, which results in a serum HCO3 <24 mEq/L. It is not a benign condition and shows an underlying disorder that needs to be corrected to minimize morbidity and mortality. The many etiologies of metabolic acidosis are classified mainly into four mechanisms: acid ingestion, increased production of acid, decreased excretion of acid, and renal or gastrointestinal (GI) bicarbonate losses.

Metabolic acidosis can be acute or chronic. Acute metabolic acidosis is comparatively more common among severely ill patients than chronic metabolic acidosis. The frequency of chronic metabolic acidosis might increase with the expected rise in chronic kidney disease (CKD) in the geriatric population.

Diagnosis

Metabolic acidosis is generally diagnosed in patients that are affected by CKD and also when the serum tCO2 concentration, which is a substitute for the bicarbonate concentration, is steadily <22 mEq/L. However, low serum tCO2 concentration is also a feature of respiratory alkalosis, and distinguishing this acid–base disorder from metabolic acidosis involves measuring systemic pH and Pco2, preferably from an arterial sample. Blood gases are rarely performed in patients with CKD with low tCO2 concentrations, are not freely available in the outpatient setting, and are needless in most of the cases. But by giving the significance of nonvolatile acid excretion in the kidney, a reasonable diagnosis of metabolic acidosis can be made without a blood gas in a patient with CKD and low tCO2 concentration.

Treatment

It covers the details of conventional and current medical therapies available in the market for the treatment of metabolic acidosis. It also provides the country-wise treatment guidelines and algorithms across the 10 emerging markets.

The DelveInsight Metabolic Acidosis market report gives a thorough understanding of metabolic acidosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.

Metabolic Acidosis Epidemiology
The Metabolic Acidosis epidemiology division provide insights about historical and current Metabolic Acidosis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of metabolic acidosis patients were found to be more in males than in females in 10 EM during the study period 2017–2030.

The disease epidemiology covered in the report provides historical as well as forecasted Metabolic Acidosis epidemiology segmented as Total Prevalent Population of CKD patients, Total Prevalent Population of Metabolic Acidosis in CKD patients, Gender-Specific Diagnosed Population of Metabolic Acidosis, Total Diagnosed Population of Metabolic Acidosis, and Total Treated Population of Metabolic Acidosis in 10EM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, Brazil, China, and Mexico from 2017 to 2030.

Country Wise- Metabolic Acidosis Epidemiology

The epidemiology section also provides the metabolic acidosis epidemiology data and key findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.

As per the DelveInsight estimates, the total prevalent cases of CKD patients in 10 EM were 263,018,799 in 2017, which are expected to reach a significantly high number by 2030.
As per the DelveInsight analysis, the total prevalent cases of metabolic acidosis in China was found to be 8,881,796 in 2017, which are expected to reach a significantly high number by 2030.
As per the DelveInsight analysis, in the year 2017, the gender-specific diagnosed cases of metabolic acidosis in Germany were 194,037 in males, and 158,757 cases in females, which are expected to reach a significantly high number by 2030.
Metabolic Acidosis Drug Chapters
This segment of the metabolic acidosis report encloses the detailed analysis of current drug therapies and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the metabolic acidosis clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.

There are no FDA-approved therapies for long-term treatment of metabolic acidosis in CKD patients; however oral alkali therapies such as sodium bicarbonate, sodium citrate, and potassium citrate/citric acid are currently prescribed by the nephrologists for treatment of metabolic acidosis.

Metabolic Acidosis Emerging Drugs

Veverimer (TRC101): Tricida

Veverimer, which is also known as TRC101, is a novel, nonabsorbed polymer that is designed for the treatment of metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract and removing it from the body through excretion in the feces. It also helps in decreasing the total amount of acid in the body and increasing blood bicarbonate. Veverimer is administered orally as a suspension in water, and it is currently under assessment by the US Food and Drug Administration (FDA) for New Drug Application (NDA) assessment.

ADV7103: Advicenne Pharma

ADV7103 is a pioneering product with a prolonged-release formulation designed to maintain a sustained release over 12 h. The product was developed as a multi particulate formulation in 2mm granules that contains two active pharmaceutical ingredients. This drug molecule is tasteless and easy to administer orally in patients of all ages. It is an investigational drug designed to treat distal renal tubular acidosis (dRTA) in patients of all ages. In December 2019, Advicenne signed a supply agreement with the pharmaceutical contract development and manufacturing organization (CDMO) Elaiapharm Lundbeck for the manufacturing of its lead product ADV7103 with a view to its worldwide commercialization as a treatment for distal Renal Tubular Acidosis (dRTA).

Products detail in the report…

Metabolic Acidosis Market Outlook
The metabolic acidosis market outlook helps to cultivate a detailed comprehension of the historical, current and forecasted market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for the better technology.

This segment gives a thorough detail of metabolic acidosis market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of treatment, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear picture of the market at first sight.

According to DelveInsight, the therapeutic market of Metabolic Acidosis in 10 emerging markets generated USD 483.62 million in 2017 and is expected to change in the forecast period 2017–2030.

Key Findings

Among the EU-5 countries, Germany had the highest market size, with USD 38.97 Million in 2017, while Italy had the lowest market size with USD 14.62 Million in 2017.
The market size of metabolic acidosis by therapies in Japan was observed as USD 45.95 Million for oral alkali therapy in 2017.
The total market size of metabolic acidosis in Brazil was observed as USD 34.06 Million in 2017.

The United States Market Outlook

This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in the United States.

EU-5 Countries: Market Outlook

This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Germany, France, Italy, Spain, and the United Kingdom.

Japan Market Outlook

This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Japan.

Brazil Market Outlook

This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Brazil.

China Market Outlook

This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in China.

Mexico Market Outlook

This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Mexico.

Metabolic Acidosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Metabolic Acidosis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Metabolic Acidosis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Metabolic Acidosis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Metabolic Acidosis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Metabolic Acidosis emerging therapies.

Reimbursement Scenario in Metabolic Acidosis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Metabolic Acidosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Metabolic Acidosis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Metabolic Acidosis Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of Metabolic Acidosis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
Comprehensive insight has been provided into the Metabolic Acidosis epidemiology and treatment in the 10EM.
Additionally, an all-inclusive account of both the current therapeutic strategies and emerging therapies for Metabolic Acidosis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of Metabolic Acidosis market; historical and forecasted is included in the report, covering drug outreach in the 10EM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the Global Metabolic Acidosis market

Report Highlights
In the coming years, Metabolic Acidosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Metabolic Acidosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Metabolic Acidosis. Launch of emerging therapies will significantly impact the Metabolic Acidosis market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metabolic Acidosis
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Metabolic Acidosis Report Insights
Patient Population
Therapeutic Approaches
Metabolic Acidosis Pipeline Analysis
Metabolic Acidosis Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Metabolic Acidosis Report Key Strengths
12-Year Plus Forecast
10EM Coverage
Metabolic Acidosis Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake
Metabolic Acidosis Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Questions
Market Insights:

What was the Metabolic Acidosis Market share (%) distribution in 2017, and how would it look like in 2030?
What would be the Metabolic Acidosis total market size as well as market size by therapies across the 10EM during the study period (2017─2030)?
What are the key findings pertaining to the market across 10EM and which country will have the largest Metabolic Acidosis market size during the study period (2017–2030)?
At what CAGR, the Metabolic Acidosis market is expected to grow in 10EM during the study period (2017–2030)?
What would be the Metabolic Acidosis market outlook across the 10EM during the study period (2017–2030)?
What would be the Metabolic Acidosis market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
How does the market size look like for the market size by therapies for each 10EM? And what are the treatment options for metabolic acidosis and revenue these treatment options expected to garner?
Which patient segment or type of therapy is more lucrative in Metabolic Acidosis? And where the emerging therapies are focusing more?
Epidemiology Insights:

What is the disease risk, burden, and unmet needs of the Metabolic Acidosis?
What is the historical Metabolic Acidosis patient pool in 10 emerging markets covering the United States, EU5 (Germany, Spain, France, Italy, the United Kingdom), Japan, China, Brazil, and Mexico?
What would be the forecasted patient pool of Metabolic Acidosis in 10 emerging markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, Brazil, and Mexico?
What will be the growth opportunities in the 10EM for the patient population pertaining to Metabolic Acidosis?
Out of all 10EM countries, which country would have the highest prevalent population of metabolic Acidosis during the study period (2017–2030)?
At what CAGR the population is expected to grow in 10EM during the study period (2017–2030)?
What are the currently available treatments of limited and extensive Metabolic Acidosis? And how the prescription patterns look like across the therapies and how does it differ across the 10EM?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the treatment of Metabolic Acidosis along with the approved therapy?
What are the current treatment guidelines for the treatment of Metabolic Acidosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, Brazil, and Mexico?
What are the Metabolic Acidosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
How many companies are developing therapies for the treatment of Metabolic Acidosis?
How many therapies are developed by each company for the treatment of a Metabolic Acidosis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metabolic Acidosis therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Metabolic Acidosis and their status?
What are the key designations that have been granted for the emerging therapies for Metabolic Acidosis?
What are the global historical and forecasted market of Metabolic Acidosis?
Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Metabolic Acidosis market
To understand the future market competition in the Metabolic Acidosis market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Metabolic Acidosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Metabolic Acidosis market
To understand the future market competition in the Metabolic Acidosis market

What is Metabolic Acidosis?

Metabolic Acidosis is a serious electrolyte disorder characterized by an imbalance in the body’s acid-base balance. Metabolic acidosis can lead to acidemia, which is defined as an arterial blood pH lower than 7.37, which itself is a result of acidosis – the process in the body that causes a low pH in blood and tissues

What was the market size of Metabolic Acidosis in 2017?

The therapeutic market of Metabolic Acidosis in 10 emerging markets was USD 483.62 million in 2017

How is epidemiology segmented for Metabolic Acidosis?

Total Prevalent Population of Chronic Kidney Disease patients, Total Prevalent Population of Metabolic Acidosis in Chronic Kidney Disease patients, Gender-Specific Diagnosed Population of Metabolic Acidosis, Total Diagnosed Population of Metabolic Acidosis, and Total Treated Population of Metabolic Acidosis

Among EU-5 countries, which country had the highest Metabolic Acidosis market size in 2017?

Among the EU-5 countries, Germany had the highest market size with USD 38.97 Million in 2017

Which companies are developing drugs for Metabolic Acidosis?

Tricida, Advicenne Pharma are developing drugs for Metabolic Acidosis

【レポートの目次】

1. Key Insights

2. Executive Summary of Metabolic Acidosis

3. SWOT Analysis of Metabolic Acidosis

4. Metabolic Acidosis: Market Overview at a Glance

5. Metabolic acidosis: Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Pathogenesis

5.4. Etiology

5.5. Effects of metabolic acidosis on the kidney

6. Diagnosis

6.1. Management of metabolic acidosis in CKD

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 10EM

7.3. Epidemiology Scenario: 10EM

7.3.1. Total Prevalence of CKD patients in the 10EM

7.3.2. Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM

7.3.3. Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM

7.3.4. Total Diagnosed Population of Metabolic Acidosis in the 10EM

7.3.5. Total Treated Population of Metabolic Acidosis in the 10EM

8. The United States Epidemiology

8.1. Total Prevalent Population of Metabolic Acidosis in the United States

8.2. Total Diagnosed Population of Metabolic Acidosis in the United States

8.3. Total Treated Population of Metabolic Acidosis in the United States

9. EU-5 Epidemiology

9.1. Germany

9.1.1. Total Prevalent Population of Metabolic Acidosis in Germany

9.1.2. Total Diagnosed Population of Metabolic Acidosis in Germany

9.1.3. Total Treated Population of Metabolic Acidosis in Germany

9.2. France

9.2.1. Total Prevalent Population of Metabolic Acidosis in France

9.2.2. Total Diagnosed Population of Metabolic Acidosis in France

9.2.3. Total Treated Population of Metabolic Acidosis in France

9.3. Italy

9.3.1. Total Prevalent Population of Metabolic Acidosis in Italy

9.3.2. Total Diagnosed Population of Metabolic Acidosis in Italy

9.3.3. Total Treated Population of Metabolic Acidosis in Italy

9.4. Spain

9.4.1. Total Prevalent Population of Metabolic Acidosis in Spain

9.4.2. Total Diagnosed Population of Metabolic Acidosis in Spain

9.4.3. Total Treated Population of Metabolic Acidosis in Spain

9.5. The United Kingdom

9.5.1. Total Prevalent Population of Metabolic Acidosis in the United Kingdom

9.5.2. Total Diagnosed Population of Metabolic Acidosis in the United Kingdom

9.5.3. Total Treated Population of Metabolic Acidosis in the United Kingdom

9.6. Japan Epidemiology

9.6.1. Total Prevalent Population of Metabolic Acidosis in Japan

9.6.2. Total Diagnosed Population of Metabolic Acidosis in Japan

9.6.3. Total Treated Population of Metabolic Acidosis in Japan

9.7. Brazil Epidemiology

9.7.1. Total Prevalent Population of Metabolic Acidosis in Brazil

9.7.2. Total Diagnosed Population of Metabolic Acidosis in Brazil

9.7.3. Total Treated Population of Metabolic Acidosis in Brazil

9.8. China Epidemiology

9.8.1. Total Prevalent Population of Metabolic Acidosis in China

9.8.2. Total Diagnosed Population of Metabolic Acidosis in China

9.8.3. Total Treated Population of Metabolic Acidosis in China

9.9. Mexico Epidemiology

9.9.1. Total Prevalent Population of Metabolic Acidosis in Mexico

9.9.2. Total Diagnosed Population of Metabolic Acidosis in Mexico

9.9.3. Total Treated Population of Metabolic Acidosis in Mexico

10. Treatment of metabolic acidosis in CKD

10.1. Recommendations according to the GRADE methodology

10.2. Adverse effects of metabolic acidosis

11. Unmet Needs

12. Patient Journey of Metabolic Acidosis

13. Attribute Analysis of Metabolic Acidosis

14. Emerging Therapies

14.1. Veverimer (TRC101): Tricida

14.1.1. Product Description

14.1.2. Other Developmental Activities

14.1.3. Clinical Development

14.1.4. Product Profile

14.2. ADV7103: Advicenne Pharma

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Development

14.2.4. Product Profile

15. Metabolic Acidosis: 10 EM Market Analysis

15.1. Key Findings

15.2. Market Size of Metabolic Acidosis in the 10EM

15.3. Market Size of Metabolic Acidosis by therapies in the 10EM

16. 10EM: Market Outlook

17. The United States: Market Size

17.1. Total Market size of Metabolic Acidosis in the United States

17.2. Market Size of Metabolic Acidosis by therapies in the United States

18. EU-5 countries: Market Size

18.1. Germany Market Size

18.1.1. Total Market size of Metabolic Acidosis in Germany

18.1.2. Market Size of Metabolic Acidosis by therapies in Germany

18.2. France Market Size

18.2.1. Total Market size of Metabolic Acidosis in France

18.2.2. Market Size of Metabolic Acidosis by therapies in France

18.3. Italy Market Size

18.3.1. Total Market size of Metabolic Acidosis in Italy

18.3.2. Market Size of Metabolic Acidosis by therapies in Italy

18.4. Spain Market Size

18.4.1. Total Market size of Metabolic Acidosis in Spain

18.4.2. Market Size of Metabolic Acidosis by therapies in Spain

18.5. The United Kingdom Market Size

18.5.1. Total Market size of Metabolic Acidosis in the United Kingdom

18.5.2. Market Size of Metabolic Acidosis by therapies in the United Kingdom

18.6. Japan: Market Size

18.6.1. Total Market size of Metabolic Acidosis in Japan

18.6.2. Market Size of Metabolic Acidosis by therapies in Japan

18.7. Brazil: Market Size

18.7.1. Total Market size of Metabolic Acidosis in Brazil

18.7.2. Market Size of Metabolic Acidosis by therapies in Brazil

18.8. China: Market Size

18.8.1. Total Market size of Metabolic Acidosis in China

18.8.2. Market Size of Metabolic Acidosis by therapies in China

18.9. Mexico: Market Size

18.9.1. Total Market size of Metabolic Acidosis in Mexico

18.9.2. Market Size of Metabolic Acidosis by therapies in Mexico

19. Access and Reimbursement Overview of Metabolic acidosis

20. KOL Views

21. Market Drivers

22. Market Barriers

23. Appendix

23.1. Bibliography

23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

Table 1: Summary of Metabolic Acidosis Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total Prevalence of CKD patients in the 10EM (2017–2030)

Table 3: Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM (2017–2030)

Table 4: Total Diagnosed Population of Metabolic Acidosis in the 10EM (2017–2030)

Table 5: Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM (2017–2030)

Table 6: Total Treated Population of Metabolic Acidosis in the 10EM (2017–2030)

Table 7: Total Prevalent Population of Metabolic Acidosis in the United States (2017–2030)

Table 8: Total Diagnosed Population of Metabolic Acidosis in the United States (2017–2030)

Table 9: Total Treated Population of Metabolic Acidosis in the United States (2017–2030)

Table 10: Total Prevalent Population of Metabolic Acidosis in Germany (2017–2030)

Table 11: Total Diagnosed Population of Metabolic Acidosis in Germany (2017–2030)

Table 12: Total Treated Population of Metabolic Acidosis in Germany (2017–2030)

Table 13: Total Prevalent Population of Metabolic Acidosis in France (2017–2030)

Table 14: Total Diagnosed Population of Metabolic Acidosis in France (2017–2030)

Table 15: Total Treated Population of Metabolic Acidosis in France (2017–2030)

Table 16: Total Prevalent Population of Metabolic Acidosis in Italy (2017–2030)

Table 17: Total Diagnosed Population of Metabolic Acidosis in Italy (2017–2030)

Table 18: Total Treated Population of Metabolic Acidosis in Italy (2017–2030)

Table 19: Total Prevalent Population of Metabolic Acidosis in Spain (2017–2030)

Table 20: Total Diagnosed Population of Metabolic Acidosis in Spain (2017–2030)

Table 21: Total Treated Population of Metabolic Acidosis in Spain (2017–2030)

Table 22: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017–2030)

Table 23: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017–2030)

Table 24: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017–2030)

Table 25: Total Prevalent Population of Metabolic Acidosis in Japan (2017–2030)

Table 26: Total Diagnosed Population of Metabolic Acidosis in Japan (2017–2030)

Table 27: Total Treated Population of Metabolic Acidosis in Japan (2017–2030)

Table 28: Total Prevalent Population of Metabolic Acidosis in Brazil (2017–2030)

Table 29: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017–2030)

Table 30: Total Treated Population of Metabolic Acidosis in Brazil (2017–2030)

Table 31: Total Prevalent Population of Metabolic Acidosis in China (2017–2030)

Table 32: Total Diagnosed Population of Metabolic Acidosis in China (2017–2030)

Table 33: Total Treated Population of Metabolic Acidosis in China (2017–2030)

Table 34: Total Prevalent Population of Metabolic Acidosis in Mexico (2017–2030)

Table 35: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017–2030)

Table 36: Total Treated Population of Metabolic Acidosis in Mexico (2017–2030)

Table 37: Commonly Prescribed Alkalinizing Agents, Dosages, and Considerations

Table 38: Recommendation according to the GRADE methodology

Table 39: Summary of recommendations

Table 40: TRC101, Clinical Trial Description

Table 41: ADV7103, Clinical Trial Description

Table 42: Market size of metabolic acidosis in the 10EM, USD Million (2017–2030)

Table 43: Market size of metabolic acidosis by therapies in the 10EM, USD Million (2017–2030)

Table 44: Market size of metabolic acidosis in the United States, USD Million (2017–2030)

Table 45: Market size of metabolic acidosis by therapies in the United States, USD Million (2017–2030)

Table 46: Market size of metabolic acidosis in Germany, USD Million (2017–2030)

Table 47: Market size of metabolic acidosis by therapies in Germany, USD Million (2017–2030)

Table 48: Market size of metabolic acidosis in France, USD Million (2017–2030)

Table 49: Market size of metabolic acidosis by therapies in France, USD Million (2017–2030)

Table 50: Market size of metabolic acidosis in Italy, USD Million (2017–2030)

Table 51: Market size of metabolic acidosis by therapies in Italy, USD Million (2017–2030)

Table 52: Market size of metabolic acidosis in Spain, USD Million (2017–2030)

Table 53: Market size of metabolic acidosis by therapies in Spain, USD Million (2017–2030)

Table 54: Market size of metabolic acidosis in the United Kingdom, USD Million (2017–2030)

Table 55: Market size of metabolic acidosis by therapies in the United Kingdom, USD Million (2017–2030)

Table 56: Market size of metabolic acidosis in Japan, USD Million (2017–2030)

Table 57: Market size of metabolic acidosis by therapies in Japan, USD Million (2017–2030)

Table 58: Market size of metabolic acidosis in Brazil, USD Million (2017–2030)

Table 59: Market size of metabolic acidosis by therapies in Brazil, USD Million (2017–2030)

Table 60: Market size of metabolic acidosis in China, USD Million (2017–2030)

Table 61: Market size of metabolic acidosis by therapies in China, USD Million (2017–2030)

Table 62: Market size of metabolic acidosis in Mexico, USD Million (2017–2030)

Table 63: Market size of metabolic acidosis by therapies in Mexico, USD Million (2017–2030)



List of Figures:

Figure 1: Mechanisms of acid-mediated tubule interstitial fibrosis in chronic kidney disease (CKD)

Figure 2: Algorithm recommended by the experts for etiological diagnosis of metabolic acidemia metabolic acidosis

Figure 3: Management of chronic metabolic acidosis (MA) in chronic kidney disease using sodium bicarbonate (NaHCO3)

Figure 4: Total Prevalence of CKD patients in the 10EM (2017–2030)

Figure 5: Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM (2017–2030)

Figure 6: Total Diagnosed Population of Metabolic Acidosis in the 10EM (2017–2030)

Figure 7: Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM (2017–2030)

Figure 8: Total Treated Population of Metabolic Acidosis in the 10EM (2017–2030)

Figure 9: Total Prevalent Population of Metabolic Acidosis in the United States (2017–2030)

Figure 10: Total Diagnosed Population of Metabolic Acidosis in the United States (2017–2030)

Figure 11: Total Treated Population of Metabolic Acidosis in the United States (2017–2030)

Figure 12: Total Prevalent Population of Metabolic Acidosis in Germany (2017–2030)

Figure 13: Total Diagnosed Population of Metabolic Acidosis in Germany (2017–2030)

Figure 14: Total Treated Population of Metabolic Acidosis in Germany (2017–2030)

Figure 15: Total Prevalent Population of Metabolic Acidosis in France (2017–2030)

Figure 16: Total Diagnosed Population of Metabolic Acidosis in France (2017–2030)

Figure 17: Total Treated Population of Metabolic Acidosis in France (2017–2030)

Figure 18: Total Prevalent Population of Metabolic Acidosis in Italy (2017–2030)

Figure 19: Total Diagnosed Population of Metabolic Acidosis in Italy (2017–2030)

Figure 20: Total Treated Population of Metabolic Acidosis in Italy (2017–2030)

Figure 21: Total Prevalent Population of Metabolic Acidosis in Spain (2017–2030)

Figure 22: Total Diagnosed Population of Metabolic Acidosis in Spain (2017–2030)

Figure 23: Total Treated Population of Metabolic Acidosis in Spain (2017–2030)

Figure 24: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017–2030)

Figure 25: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017–2030)

Figure 26: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017–2030)

Figure 27: Total Prevalent Population of Metabolic Acidosis in Japan (2017–2030)

Figure 28: Total Diagnosed Population of Metabolic Acidosis in Japan (2017–2030)

Figure 29: Total Treated Population of Metabolic Acidosis in Japan (2017–2030)

Figure 30: Total Prevalent Population of Metabolic Acidosis in Brazil (2017–2030)

Figure 31: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017–2030)

Figure 32: Total Treated Population of Metabolic Acidosis in Brazil (2017–2030)

Figure 33: Total Prevalent Population of Metabolic Acidosis in China (2017–2030)

Figure 34: Total Diagnosed Population of Metabolic Acidosis in China (2017–2030)

Figure 35: Total Treated Population of Metabolic Acidosis in China (2017–2030)

Figure 36: Total Prevalent Population of Metabolic Acidosis in Mexico (2017–2030)

Figure 37: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017–2030)

Figure 38: Total Treated Population of Metabolic Acidosis in Mexico (2017–2030)

Figure 39: Adverse effects of acute metabolic acidosis

Figure 40: Adverse effects of chronic metabolic acidosis

Figure 41: Increased mean serum bicarbonate (SBC) throughout the 2-week treatment period

Figure 42: Increased mean serum bicarbonate (SBC) throughout the 2-week treatment period

Figure 43: Market size of metabolic acidosis in the 10EM, USD Million (2017–2030)

Figure 44: Market size of metabolic acidosis by therapies in the 10EM, USD Million (2017–2030)

Figure 45: Market size of metabolic acidosis in the United States, USD Million (2017–2030)

Figure 46: Market size of metabolic acidosis by therapies in the United States, USD Million (2017–2030)

Figure 47: Market size of metabolic acidosis in Germany, USD Million (2017–2030)

Figure 48: Market size of metabolic acidosis by therapies in Germany, USD Million (2017–2030)

Figure 49: Market size of metabolic acidosis in France, USD Million (2017–2030)

Figure 50: Market size of metabolic acidosis by therapies in France, USD Million (2017–2030)

Figure 51: Market size of metabolic acidosis in Italy, USD Million (2017–2030)

Figure 52: Market size of metabolic acidosis by therapies in Italy, USD Million (2017–2030)

Figure 53: Market size of metabolic acidosis in Spain, USD Million (2017–2030)

Figure 54: Market size of metabolic acidosis by therapies in Spain, USD Million (2017–2030)

Figure 55: Market size of metabolic acidosis in the United Kingdom, USD Million (2017–2030)

Figure 56: Market size of metabolic acidosis by therapies in the United Kingdom, USD Million (2017–2030)

Figure 57: Market size of metabolic acidosis in Japan, USD Million (2017–2030)

Figure 58: Market size of metabolic acidosis by therapies in Japan, USD Million (2017–2030)

Figure 59: Market size of metabolic acidosis in Brazil, USD Million (2017–2030)

Figure 60: Market size of metabolic acidosis by therapies in Brazil, USD Million (2017–2030)

Figure 61: Market size of metabolic acidosis in China, USD Million (2017–2030)

Figure 62: Market size of metabolic acidosis by therapies in China, USD Million (2017–2030)

Figure 63: Market size of metabolic acidosis in Mexico, USD Million (2017–2030)

Figure 64: Market size of metabolic acidosis by therapies in Mexico, USD Million (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[代謝性アシドーシス(MA)治療薬の世界市場:インサイト・疫学・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆